A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy

NaSingle-groupOpen-labelTreatment

This study is a single-center, open-label clinical trial of single-dose of CAR T-cells in subjects with relapsed/refractory hematologic malignancy.

Evaluation	Drug	Modality	Dose	Route
Subject	Anti-CD30 CAR T cells	Cell therapy	3e+06 cells/kg	Intravenous
Subject	Anti-CD30 CAR T cells	Cell therapy	6e+06 cells/kg	Intravenous
Subject	Anti-CD30 CAR T cells	Cell therapy	1e+07 cells/kg	Intravenous
Subject	anti-CD19 CAR-T cells	Cell therapy	100000 cells/kg	Intravenous
Subject	anti-CD19 CAR-T cells	Cell therapy	300000 cells/kg	Intravenous
Subject	anti-CD19 CAR-T cells	Cell therapy	1e+06 cells/kg	Intravenous
Subject	anti-CD20/CD30-CAR T-cells	Cell therapy	1e+06 cells/kg	Intravenous
Subject	anti-CD20/CD30-CAR T-cells	Cell therapy	3e+06 cells/kg	Intravenous
Subject	anti-CD20/CD30-CAR T-cells	Cell therapy	1e+07 cells/kg	Intravenous
Background	Cyclophosphamide	Other / unclassified	250 mg/m2	Intravenous
Background	Fludarabine	Small molecule	25 mg/m2	Intravenous